上咽頭癌における臨床経過と抗EBウイルス抗体価との関連について

概要

論文の詳細を見る
The antibody against viral capsid antigen (VCA) of Epstein-Bair (EB) virus was studied in 40 patients with malignant tumors of the nasopharynx. Out of 40 cases, there were 32 carcinomas (squamous cell carcinoma 18, undifferentiated carcinoma 7, lymphoepithelioma 3, transitional cell carcinoma 2 and adenoid cystic carcinoma 2) and 8 sarcomas. Patients were treated by radiotherapy alone, radiotherapy accompanied by chemotherapy or radiotherapy followed by radical neck dissection. Titration of anti-VCA antibody was done by means of fluorescent antibody indirect method (Kawamuras method). The results obtained were as follows: 10 patients before tretment had a geometric mean titer (GMT) of 1 : 421 and a positive rate of 60%. In 13 patients during treatment, there was an increase in the anti-VCA antibodies (GMT 1 : 880) and the positive rate was up to 77%. In patients at the end of treatment, GMT was 1 : 1381 and the positive rate 89%. From the above results, it is concluded that in the present study the anti-VCA antibodies increased during and at the end of tretment. In 16 patients with recurrence or metastasis a mean titer was 1 : 1809 and a positive rate was 100%. On the contrary, 6 patients in remission of more than 3 years had a titer of 1 : 319 and a positive rate of 50% . Therefore, it is concluded that in cases of recurrence or metastasis, there was a significant increase in the anti-VCA antibodies and in cases in remission of more than 3 years, there was a decrease in the antibodies.We conclude that the anti-VCA titer can be applied clinically as an useful parameter for the prognosis of the nasopharyngeal carcinoma.
社団法人日本耳鼻咽喉科学会の論文

上咽頭癌における臨床経過と抗EBウイルス抗体価との関連について

スポンサーリンク

概要

著者

関連論文

スポンサーリンク